Plus   Neg

Sanofi Reports Phase 3 Topline Trial Results Of Iniparib & Otamixaban

Sanofi (SNYNF,SNY) announced topline results of two Phase 3 studies of its investigational compounds iniparib and otamixaban respectively.

The randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer failed to meet its primary endpoint. During the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone.

Topline results of the completed Phase 3 trial of the investigational anticoagulant otamixaban demonstrated that the study failed to meet its primary endpoint of superiority over current therapy. In the TAO study, due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation acute coronary syndrome patients planned for early invasive strategy. The primary endpoint of the Phase 3 TAO trial was the reduction of all-cause mortality or new heart attacks.

As a result, the company would terminate the investigational program with otamixaban, an injectable factor Xa inhibitor.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Saudi Arabia's oil major Aramco is reportedly planning to list its much hyped initial public offering on the Saudi stock market, Tadawu only. Earlier, the Dhahran-based Saudi Arabian national petroleum company was planning for a wider international listing. Following a disastrous week of public-relations fiascoes involving transportation of pets, United Airlines said Tuesday it is suspending its Petsafe program with immediate effect. PetSafe is United Airlines' specially designed program for transporting animals that are not eligible to travel in the aircraft cabin. The program offers airport-to-airport travel for animals to nearly 300 destinations. Chipotle Mexican Grill, the Mexican food-chain that continues to struggle from its food-borne illness scandal, on Tuesday said it has appointed Chris Brandt as its new Chief Marketing Officer to replace Mark Crumpacker, who resigned last week. Most recently, Brandt worked at Bloomin' Brands, where...
comments powered by Disqus
Follow RTT